Video

Pharmacist Medication Insights: Emicizumab (Hemlibra) for Hemophilia A

Emicizumab (Hemlibra, Roche) is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with or without factor VIII inhibitors.

Emicizumab (Hemlibra, Roche) is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with or without factor VIII (FVIII) inhibitors.

Hemophilia A is an inherited disorder that causes an individual’s blood to not clot properly, leading to uncontrolled and spontaneous bleeding. It affects approximately 320,000 people worldwide and between 50% and 60% of these patients have a severe form of the disorder.

Patients with hemophilia A either have very little or no FVIII, a clotting factor that helps form clots and stop bleeding in healthy individuals. Although many patients with hemophilia A receive FVIII as part of their treatment, the development of inhibitors to FVIII replacement therapies can be a major complication. Inhibitors are antibodies developed by the body’s immune system that bind to and block the replacement FVIII, limiting its ability to control bleeding.

Data from the pooled, 3-year follow-up of 401 patients with hemophilia A from the HAVEN studies 1 through 4 show that emicizumab maintained low treated bleed rates and was well tolerated in patients of all ages with hemophilia A, both with and without FVIII inhibitors.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com